Improving the outcome of patients with leptomeningeal cancer: new clinical trials and experimental therapies.

Kurt Jaeckle

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Current therapy for leptomeningeal metastases is predominantly palliative. In an effort to improve disease control and patient outcome, new strategies are being developed to target the cerebrospinal space. These include new intrathecal formulations of systemic chemotherapy as well as the development of radiolabeled immunoconjugates and antitumor antibodies. Furthermore, there is debate as to the optimal strategy of drug delivery for leptomeningeal tumor.

Original languageEnglish (US)
Pages (from-to)181-193
Number of pages13
JournalCancer Treatment and Research
Volume125
StatePublished - Jan 1 2005

Fingerprint

Immunoconjugates
Investigational Therapies
Clinical Trials
Neoplasm Metastasis
Drug Therapy
Antibodies
Pharmaceutical Preparations
Neoplasms
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

@article{8087bb0ba1144c4287ad48fa0f856498,
title = "Improving the outcome of patients with leptomeningeal cancer: new clinical trials and experimental therapies.",
abstract = "Current therapy for leptomeningeal metastases is predominantly palliative. In an effort to improve disease control and patient outcome, new strategies are being developed to target the cerebrospinal space. These include new intrathecal formulations of systemic chemotherapy as well as the development of radiolabeled immunoconjugates and antitumor antibodies. Furthermore, there is debate as to the optimal strategy of drug delivery for leptomeningeal tumor.",
author = "Kurt Jaeckle",
year = "2005",
month = "1",
day = "1",
language = "English (US)",
volume = "125",
pages = "181--193",
journal = "Cancer Treatment and Research",
issn = "0927-3042",
publisher = "Springer Netherlands",

}

Improving the outcome of patients with leptomeningeal cancer : new clinical trials and experimental therapies. / Jaeckle, Kurt.

In: Cancer Treatment and Research, Vol. 125, 01.01.2005, p. 181-193.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Improving the outcome of patients with leptomeningeal cancer

T2 - new clinical trials and experimental therapies.

AU - Jaeckle, Kurt

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Current therapy for leptomeningeal metastases is predominantly palliative. In an effort to improve disease control and patient outcome, new strategies are being developed to target the cerebrospinal space. These include new intrathecal formulations of systemic chemotherapy as well as the development of radiolabeled immunoconjugates and antitumor antibodies. Furthermore, there is debate as to the optimal strategy of drug delivery for leptomeningeal tumor.

AB - Current therapy for leptomeningeal metastases is predominantly palliative. In an effort to improve disease control and patient outcome, new strategies are being developed to target the cerebrospinal space. These include new intrathecal formulations of systemic chemotherapy as well as the development of radiolabeled immunoconjugates and antitumor antibodies. Furthermore, there is debate as to the optimal strategy of drug delivery for leptomeningeal tumor.

UR - http://www.scopus.com/inward/record.url?scp=27744435324&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27744435324&partnerID=8YFLogxK

M3 - Review article

C2 - 16211890

AN - SCOPUS:27744435324

VL - 125

SP - 181

EP - 193

JO - Cancer Treatment and Research

JF - Cancer Treatment and Research

SN - 0927-3042

ER -